Comparative evaluation of 111In-labeled NOTA-conjugated affibody molecules for visualization of HER3 expression in malignant tumors

Oncology Reports

Volumn 34, Issue 2, 2015, Pages 1042-1048

  Andersson, Ken G ^a   Rosestedt, Maria ^b   Varasteh, Zohreh ^b   Malm, Magdalena ^a   Sandström, Mattias ^b   Tolmachev, Vladimir ^b   Löfblom, John ^a   Ståhl, Stefan ^a   Orlova, Anna ^b  

^a ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Affibody molecules; HER3; Indium 111; Molecular imaging; NOTA

Indexed keywords

DIAGNOSTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 3; INDIUM HISTIDYLGLUTAMYLHISTIDYLGLUTAMYLHISTIDYLGLTAMIC ACID Z 08698 NOTA CONJUGATE IN 111; INDIUM HISTIDYLGLUTAMYLHISTIDYLGLUTAMYLHISTIDYLGLUTAMIC ACID Z 08699 NOTA CONJUGATE IN 111; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; ERBB3 PROTEIN, HUMAN; HYBRID PROTEIN; INDIUM;

ANALYTICAL PARAMETERS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING KINETICS; BREAST CANCER CELL LINE; BREAST TUMOR; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG SPECIFICITY; DRUG TUMOR LEVEL; FEMALE; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; KIDNEY; LIGAND BINDING; MOLECULAR IMAGING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RADIOACTIVITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR TO BLOOD RATIO; TUMOR TO BONE RATIO; TUMOR TO LIVER RATIO; TUMOR TO LUNG RATIO; TUMOR TO MUSCLE RATIO; TUMOR TO SALIVARY GLAND RATIO; TUMOR TO SMALL INTESTINE RATIO; TUMOR TO SPLEEN RATIO; TUMOR TO STOMACH RATIO; TUMOR XENOGRAFT; ANIMAL; CANCER TRANSPLANTATION; CHEMISTRY; HUMAN; METABOLISM; SCINTISCANNING; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; INDIUM RADIOISOTOPES; MICE; MOLECULAR IMAGING; NEOPLASM TRANSPLANTATION; RADIOPHARMACEUTICALS; RECEPTOR, ERBB-3; RECOMBINANT FUSION PROTEINS;

EID: 84931352417     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.4046     Document Type: Article

References (25)

1. Baselga J and Swain SM: Novel anticancer targets: Revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 9: 463-475, 2009.
2. Lipton A, Goodman L, Leitzel K, Cook J, Sperinde J, Haddad M, Köstler WJ, Huang W, Weidler JM, Ali S, et al: HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer. Breast Cancer Res Treat 141: 43-53, 2013.
3. Aurisicchio L, Marra E, Roscilli G, Mancini R and Ciliberto G: The promise of anti-ErbB3 monoclonals as new cancer therapeutics. Oncotarget 3: 744-758, 2012.
4. Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137, 2001.
5. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM and Moasser MM: Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445: 437-441, 2007.
6. Kruser TJ and Wheeler DL: Mechanisms of resistance to HER family targeting antibodies. Exp Cell Res 316: 1083-1100, 2010.
7. Hamburger AW: The role of ErbB3 and its binding partners in breast cancer progression and resistance to hormone and tyrosine kinase directed therapies. J Mammary Gland Biol Neoplasia 13: 225-233, 2008.
8. Wu Y, Zhang Y, Wang M, Li Q, Qu Z, Shi V, Kraft P, Kim S, Gao Y, Pak J, et al: Downregulation of HER3 by a novel antisense oligonucleotide, EZN-3920, improves the antitumor activity of EGFR and HER2 tyrosine kinase inhibitors in animal models. Mol Cancer Ther 12: 427-437, 2013.
9. Malm M, Kronqvist N, Lindberg H, Gudmundsdotter L, Bass T, Frejd FY, Höidén-Guthenberg I, Varasteh Z, Orlova A, Tolmachev V, et al: Inhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversification. PLoS One 8: e62791, 2013.
10. 89Zr-RG7116. MAbs 6: 1051-1058, 2014.
11. Wehrenberg-Klee E, Turker NS, Chang B, Heidari P and Mahmood U: Development of a HER3 PET probe for breast cancer imaging. J Nucl Med 55 (Suppl 1): s550, 2014.
12. Wester HJ and Kessler H: Molecular targeting with peptides or peptide-polymer conjugates: Just a question of size? J Nucl Med 46: 1940-1945, 2005.
13. HER3:08699 affibody molecule. Eur J Nucl Med Mol Imaging 41: 1450-1459, 2014.
14. Löfblom J, Feldwisch J, Tolmachev V, Carlsson J, Ståhl S and Frejd FY: Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett 584: 2670-2680, 2010.
15. 68Ga-labeled affibody molecules. J Nucl Med 51: 892-897, 2010.
16. 111In-ABY-025 affibody molecule. J Nucl Med 55: 730-735, 2014.
17. Tolmachev V, Altai M, Sandström M, Perols A, Karlström AE, Boschetti F and Orlova A: Evaluation of a maleimido derivative of NO TA for site-specific labeling of affibody molecules. Bioconjug Chem 22: 894-902, 2011.
18. Ahlgren S, Orlova A, Rosik D, Sandström M, Sjöberg A, Baastrup B, Widmark O, Fant G, Feldwisch J and Tolmachev V: Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules. Bioconjug Chem 19: 235-243, 2008.
19. 125I. J Med Chem 54: 3817-3826, 2011.
20. Tolmachev V, Tran TA, Rosik D, Sjöberg A, Abrahmsén L and Orlova A: Tumor targeting using affibody molecules: Interplay of affinity, target expression level, and binding site composition. J Nucl Med 53: 953-960, 2012.
21. IGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours. Eur J Nucl Med Mol Imaging 40: 439-449, 2013.
22. HER2:2395 in a mouse model for ovarian cancer. J Nucl Med 53: 146-153, 2012.
23. Björke H and Andersson K: Measuring the affinity of a radioligand with its receptor using a rotating cell dish with in situ reference area. Appl Radiat Isot 64: 32-37, 2006.
24. HER2:342-pep2: implications for development of labeled tracers. Cancer Biother Radiopharm 23: 435-442, 2008.
25. Razumienko EJ, Scollard DA and Reilly RM: Small-animal SPECT/CT of HER2 and HER3 expression in tumor xenografts in athymic mice using trastuzumab Fab-heregulin bispecific radioimmunoconjugates. J Nucl Med 53: 1943-1950, 2012.